Once again drug price transparency is in the news. Now it appears that efforts to improve pricing visibility are dead on arrival. If we look at recent actions by Pfizer and Mylan, it may well be. At the very least, their actions cast doubt Brent Saunders’ notion of a “social contract” between drug companies and patients. [1] Pfizer Sues Texas Pfizer and the Texas Health and Human Services Commission are in court. Medicaid…
The post Is Drug Price Transparency DOA? appeared first on Whitelaw Compliance Group, LLC.